Related Experiment Video
Updated: May 5, 2026
Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes hPSC-CMs Using Multi-electrode Arrays MEAs
Published on: May 12, 2017
Induced pluripotent stem cells as cardiac arrhythmic in vitro models and the impact for drug discovery
Tomo Sarić1, Marcel Halbach, Markus Khalil
1University of Cologne, Institute for Neurophysiology, Center for Physiology and Pathophysiology, Medical Center , Robert Koch Str. 39, 50931 Cologne , Germany +49 221 478 86686 ; +49 221 478-3834 ; tomo.saric@uni-koeln.de.
Introduction:
The development of new antiarrhythmic agents is challenging and is hampered by high attrition rate of novel drug candidates. One of the reasons for this is limited predictability of existing preclinical models for drug assessment. Cardiomyocytes (CMs) derived from disease-specific induced pluripotent stem cells (iPSC) represent a novel in vitro cellular model of cardiac arrhythmias with an unprecedented potential for generating new mechanistic insight into disease pathophysiology and improving the process of drug development.
Areas Covered:
This review outlines recent studies demonstrating the suitability and limitations of iPSC-derived CMs (iPS-CMs) for in vitro modeling inherited arrhythmias and drug testing. The authors focus on channelopathies and outline the properties of iPS-CMs, highlighting their utility and limitations for investigating the mechanism of cardiac arrhythmias and drug discovery.
Expert Opinion:
The iPS-CMs represent a valuable addition to the already existing armamentarium of cardiac arrhythmic models. However, the superiority of iPS-CMs over other arrhythmia models has not yet been rigorously established and the limitations of the model must be overcome before its full potential for antiarrhythmic drug discovery can be realized. Nevertheless, iPS cell-based platforms hold a great potential for increasing our knowledge about cellular arrhythmia mechanisms and improving the drug discovery process.
Insights
Induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) offer a promising in vitro model for studying cardiac arrhythmias and developing antiarrhythmic drugs. While valuable, their limitations require further research to fully realize their potential in drug discovery.
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Pharmacology
Background:
- Developing new antiarrhythmic agents is hindered by high attrition rates and limited preclinical model predictability.
- Disease-specific induced pluripotent stem cells (iPSCs) can generate cardiomyocytes (CMs) for novel in vitro cardiac arrhythmia models.
- These iPSC-derived CMs (iPS-CMs) hold potential for mechanistic insights and improved drug development.
Purpose of the Study:
- To review the suitability and limitations of iPS-CMs for modeling inherited arrhythmias.
- To evaluate iPS-CMs for antiarrhythmic drug testing, focusing on channelopathies.
- To highlight the utility and constraints of iPS-CMs in arrhythmia research and drug discovery.
Main Methods:
- Review of recent studies on iPSC-derived cardiomyocyte models.
- Focus on channelopathies as a model for inherited arrhythmias.
- Analysis of iPS-CM properties for drug discovery applications.
Main Results:
- iPS-CMs are a valuable addition to existing cardiac arrhythmia models.
- Studies demonstrate the utility of iPS-CMs for in vitro modeling and drug testing.
- Limitations of iPS-CMs in predicting drug efficacy need to be addressed.
Conclusions:
- iPS-CMs show significant potential for advancing our understanding of cardiac arrhythmias.
- Further research is needed to rigorously establish iPS-CM superiority over other models.
- Overcoming current limitations will unlock the full potential of iPS-CMs for antiarrhythmic drug discovery.
More Related Videos
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
